HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advances
Net income fell to $15.9 million from $455.0 million a year earlier, a decline driven by a large one-time gain in 2025, while ELUNATE and SULANDA sales each grew over 40%.
HUTCHMED (China) Limited reported financial results for the six months ended June 30, 2026 on July 30, 2026. Net income attributable to HUTCHMED was $15.9 million, compared with $455.0 million in H1 2025 which had included a $416.3 million gain on divestment of 45% of Shanghai Hutchison Pharmaceuticals Limited, and the company maintained a strong cash balance of $1.37 billion.1
ELUNATE (fruquintinib in China) sales rose 41% to $60.8 million as reimbursement coverage expanded for endometrial cancer and the drug was approved for kidney cancer, while SULANDA sales rose 45% to $18.4 million, boosted by an upgraded recommendation in Chinese oncology guidelines for neuroendocrine tumors.1 FRUZAQLA (fruquintinib ex-China) in-market sales outside the US rose about 70% to $68.9 million in H1 2026.1
The NDA for ELUNATE combined with sintilimab was approved in China in May 2026 for second-line kidney cancer, backed by FRUSICA-2 Phase III data showing median progression-free survival of 22.2 months versus 6.9 months in the control group.1 Sovleplenib's NDA for warm autoimmune hemolytic anemia was accepted in China in April 2026, supported by ESLIM-02 Phase III data showing a durable response rate of 66.0%, following an earlier NDA acceptance for immune thrombocytopenia in February 2026, with both indications receiving priority review.1
On the pipeline side, the company initiated clinical trials of ATTC candidates HMPL-A251 in December 2025 and HMPL-A580 in March 2026, and had its HMPL-A830 clinical trial application approved in July 2026 based on a different ATTC payload platform.1
HUTCHMED reiterated full year 2026 guidance for Oncology/Immunology consolidated revenue in the range of $330 million to $450 million.1 Separately, Ipsen voluntarily withdrew TAZVERIK from all its markets in March 2026 following emerging safety data from the SYMPHONY-1 trial.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.